

[Paracetamol \(acetaminophen\)](#)

Statut de médicament essentiel

Section:

[5. Medicines for neurological disorders](#) [5.1. Medicines for central nervous system disorders](#) [5.1.5. Medicines for headache disorders](#) [5.1.5.1. Medicines for acute migraine attacks](#)

Codes ATC: [N02BE01](#)

EMLc

Indication

Migraine Code ICD11: [8A80.Z](#)

INN

Paracetamol

Type de médicament

Chemical agent

Type de liste

Liste de base

Additional notes

*The presence of both 120 mg/5 mL and 125mg/5mL oral liquid strengths on the same market would cause confusion in prescribing and dispensing and should be avoided

Formulations

Oral > Liquid: 125 mg per 5 mL (EMLc) ; 120 mg per 5 mL (EMLc) ; 250 mg per 5 mL (EMLc)

Local > Rectal > Suppository: 250 mg (EMLc)

Oral > Solid > dispersible tablet: 100 mg (EMLc) ; 250 mg (EMLc)

Oral > Solid > tablet: 250 mg ; 325 mg ; 500 mg

Historique des statuts LME

Ajouté pour la première fois en 1987 ([TRS 770](#))

Modifié en 2007 ([TRS 950](#))

Modifié en 2017 ([TRS 1006](#))

Modifié en 2023 ([TRS 1049](#))

Sexe

Tous

Âge

Aussi recommandé pour les enfants

Équivalence thérapeutique

La recommandation concerne ce médicament spécifique

Renseignements sur le brevet

Patents have expired in most jurisdictions

Lire la suite [sur les brevets.](#)

Wikipédia

[Paracetamol \(acetaminophen\)](#)

DrugBank

[Paracetamol \(Acetaminophen\)](#)

Résumé des preuves et recommandation du comité d'experts

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the deletion of the 100 mg tablet formulation from the EML and EMLc - strengths of paracetamol tablets should be specified rather than given in a range - the addition of a 250 mg strength suppository formulation to the EMLc - the addition of paracetamol dispersible tablets (100 mg and 250 mg) to the EMLc - the addition of 250 mg/5mL strength oral liquid formulation to the EMLc - the addition of a note stating "the presence of both 120 mg/5 mL and 125mg/5mL oral liquid strengths on the same market would cause confusion in prescribing and dispensing and should be avoided"